PITTSBURGH and LONDON, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug ...

Researchers at the University of Colorado Anschutz Medical Campus have helped confirm the dosing, safety and effectiveness of a drug formulation designed for treating children with human ...

The fixed-dose combination of abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg tablets for oral suspension is not recommended in patients with resistance-associated integrase substitutions or ...

LONDON and PITTSBURGH — Mylan on Thursday announced that its subsidiary, Mylan Labs, was granted tentative approval from the Food and Drug Administration for two dosages of abacavir/lamivudine tablets ...

Tight development timelines and accelerated approval pathways favor simple, cost-effective capsule formulations. Capsules are a common oral solid dosage form and are produced in a variety of shapes, ...

Follows recent agreement with ViiV Healthcare in collaboration with Clinton Health Access Initiative to expand reach of pediatric formulation of Abacavir/Lamivudine to resource-limited settings Mylan ...

Chicago, Sept. 16, 2003 – An unplanned interim analysis of a study comparing tenofovir disoproxil fumarate (TDF) to efavirenz (EFV) - both given in combination with a fixed-dose investigational ...

Advancements in soft capsule technology can enable the development of soft capsule formulations, which are becoming the preferred method of oral administration. Soft capsule formulation technology ...

Researchers at the University of Colorado Anschutz Medical Campus have helped confirm the dosing, safety and effectiveness of a drug formulation designed for treating children with human ...

Researchers at the University of Colorado Anschutz Medical Campus have contributed to the confirmation of the dose, safety, and efficacy of a medication formulation intended to treat children infected ...

The fixed-dose combination of abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg tablets for oral suspension is indicated for the treatment of HIV-1 infection in paediatric patients weighing at least 6 ...